|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
69,020,000 |
Market
Cap: |
106.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6003 - $1.92 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
94,704 |
3,933,628 |
Total Buy Value |
$0 |
$0 |
$64,854 |
$18,622,222 |
Total People Bought |
0 |
0 |
4 |
4 |
Total Buy Transactions |
0 |
0 |
10 |
76 |
Total Shares Sold |
0 |
0 |
0 |
85,082 |
Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Svennilson Peter |
General Partner |
|
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
- |
|
Svennilson Peter |
General Partner |
|
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
- |
|
Goeddel David V |
Managing Partner |
|
2020-07-22 |
4 |
B |
$18.00 |
$3,474 |
D/D |
193 |
1,540,264 |
3.84 |
- |
|
Ponoi Capital, Lp |
General Partner |
|
2020-07-22 |
4 |
B |
$18.00 |
$3,474 |
D/D |
193 |
1,540,264 |
2.37 |
- |
|
Goeddel David V |
Managing Partner |
|
2020-07-21 |
4 |
OE |
$13.35 |
$320,400 |
D/D |
24,000 |
44,000 |
|
- |
|
Ponoi Capital, Lp |
General Partner |
|
2020-07-21 |
4 |
OE |
$13.35 |
$320,400 |
D/D |
24,000 |
44,000 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2020-07-01 |
4 |
AS |
$18.79 |
$472,728 |
D/D |
(25,000) |
1,020,005 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2020-06-15 |
4 |
AS |
$21.15 |
$541,166 |
D/D |
(25,000) |
1,045,005 |
|
- |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2020-05-15 |
4 |
S |
$22.00 |
$34,364 |
D/D |
(1,562) |
182 |
|
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
D/D |
112,602 |
1,540,071 |
2.45 |
- |
|
Svennilson Peter |
Director |
|
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
I/I |
112,602 |
17,706,978 |
2.25 |
- |
|
Column Group Iii Gp, Lp |
General Partner |
|
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
D/D |
112,602 |
1,540,071 |
2.45 |
- |
|
Goeddel David V |
Director |
|
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
I/I |
112,602 |
17,896,978 |
2.25 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
D/D |
123,728 |
1,427,469 |
2.45 |
- |
|
Svennilson Peter |
Director |
|
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
I/I |
123,728 |
17,594,376 |
2.25 |
- |
|
Column Group Iii Gp, Lp |
General Partner |
|
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
D/D |
123,728 |
1,427,469 |
2.45 |
- |
|
Goeddel David V |
Director |
|
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
I/I |
123,728 |
17,784,376 |
2.25 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
D/D |
14,587 |
1,303,741 |
2.45 |
- |
|
Svennilson Peter |
Director |
|
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
I/I |
14,587 |
17,470,648 |
2.25 |
- |
|
Column Group Iii Gp, Lp |
General Partner |
|
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
D/D |
14,587 |
1,303,741 |
2.45 |
- |
|
Goeddel David V |
Director |
|
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
I/I |
14,587 |
17,660,648 |
2.25 |
- |
|
Column Group Iii Gp, Lp |
General Partner |
|
2020-04-02 |
4 |
B |
$12.40 |
$184,140 |
D/D |
14,850 |
1,289,154 |
2.45 |
- |
|
Column Group Ii Gp, Lp |
General Partner |
|
2020-04-02 |
4 |
B |
$12.40 |
$184,140 |
D/D |
14,850 |
1,289,154 |
2.45 |
- |
|
499 Records found
|
|
Page 10 of 20 |
|
|